With daily case counts revealing a plateau in numbers of infections and tests, diagnostics companies are bracing for an inconvenient but expected fall in demand for COVID-19 test kits. Part of the game plan involves launching a quest for alternate revenue streams, especially once vaccination begins. When the pandemic began early last year, Chennai-based medical devices manufacturer Trivitron began investing in manufacturing RT-PCR test kits at its plant in Chennai. Today, the company has a capacity of two crore COVID test kits per month, at its plants in Chennai and Vizag, which account for 60 percent of Trivitron's 2020 revenues. With daily case counts revealing a plateau in numbers of infections and tests, diagnostics companies are bracing for an inconvenient but expected fall in demand for COVID-19 test kits. Part of the game plan involves launching a quest for alternate revenue streams, especially once vaccination begins. When the pandemic began early last year, Chennai-based medical devices manufacturer Trivitron began investing in manufacturing RT-PCR test kits at its plant in Chennai. Today, the company has a capacity of two crore COVID test kits per month, at its plants in Chennai and Vizag, which account for 60 percent of Trivitron's 2020 revenues.